Kalaris releases corporate presentation with TH103 trial updates but no specific figures disclosed

Kalaris Therapeutics, Inc.

Presentation includes timelines for reporting Phase 1b/2 data of TH103 and plans to initiate Phase 3; no dates or numbers given in filing.
Cash runway guidance mentioned in the presentation; precise amount or duration not provided in the 8-K.
Presentation to be used at Leerink Partners Global Healthcare Conference and other investor meetings.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.